Stuart Cable is a trusted advisor to a number of the world’s most innovative technology and life sciences companies. From emerging startups to established global brands in the technology and life sciences sectors, Stuart’s visionary leadership, business acumen and unparalleled experience allows him to navigate the increasingly rapid pace of change and serve the varied needs of the innovators shaping the future.
Stuart’s boundless commitment to innovation has also made him the driving force behind a number of the firm’s pioneering programs, initiatives and partnerships. Most recently, Stuart co-founded with his partner, Lisa Haddad, GOOD Directors, a first-of-its-kind national leadership program designed to create opportunities for next-generation, BIPOC, LGBTQ+ and women leaders to join Boards of Directors of public companies. He also founded Goodwin's Directors Forum, the firm's annual forum designed specifically for the directors of the leading public companies, and Goodwin Labs, a pro bono program supporting life sciences startup incubators.
Stuart counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters. He represents buyers, sellers and investment banks in his M&A practice, as well as the private equity and venture sources investing in such companies and investment banks serving such industries.
Stuart’s biotechnology and healthcare representative clients include: Alltrna, Amag Pharmaceuticals, AnaptysBio, Apriori Bio, AvroBio, Aura, Cerevel, Flagship Pioneering, Generate, Inzen, Laronde, Mirati, Moderna, ModeX, New York Stem Cell Foundation, PAREXEL, Pioneering Medicines, Repertoire Immune Medicines, Shields Healthcare Solutions, Sonata, Tessera Therapeutics, Valo Health, Vesalius, Vesigen, and YourBio Health.
His innovative technology representative clients include: Ansys, Cimpress, Citrix, iRobot, PTC, Plug Power, Ritchie Bros.
- Represented financial advisor to Pfizer in the 2023 acquisition of Seagen ($43 billon)
- Represented financial advisor to Imago Biosciences in the 2022 acquisition by Merck ($1.35 billion)
- Forma Therapeutics in its 2022 sale to Novo Nordisk ($1.1 billion)
- Checkmate Pharmaceuticals in its 2022 sale to Regeneron Pharmaceuticals ($250 million)
- Shields Health Solutions in its sale to Walgreens ($1.37 billion)
- Generate Biomedicines on its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities ($1.9 billion)
- Represented financial advisor to Acceleron Pharma in Merck’s 2021 acquisition ($11.5 billion)
- Shields Health Solutions, its management team and UMass in connection with Walgreens Boots Alliance’s 2021 majority investment in Shields ($970 million)
- Trillium Therapeutics in its 2021 acquisition by Pfizer ($2.26 billion)
- Valo Health in its announced 2021 deSPAC business combination with Khosla Ventures Acquisition Co. ($2.8 billion)
- Cerevel Therapeutics in its 2021 deSPAC business combination with ARYA Sciences Acquisition Corp II ($440 million)
- Represented financial advisor to Pandion Therapeutics’ in its 2021 sale to Merck ($1.85 billion)
- MyoKardia in its 2020 acquisition by Bristol Myers Squibb ($13.1 billion)
- Represented financial advisor in Immunomedics’ 2020 sale to Gilead Sciences, Inc. ($20 billion)
- Represented financial advisor in Principia Biopharma’s 2020 acquisition by Sanofi ($3.68 billion)
- Represented financial advisor in Forty Seven’s 2020 acquisition by Gilead Sciences ($4.9 billion)
- AMAG Pharmaceuticals in its 2020 sale to Covis Group ($500 million)
- Represented financial advisor to Arqule’s in its 2020 acquisition by Merck ($2.7 billion)
- Spark Therapeutics in its 2019 sale to Roche ($4.4 billion)
- Keryx in its 2018 merger with Akebia ($1.3 billion)
- Foundation Medicine in its 2015 majority sale to Roche ($1 billion) and the subsequent 2018 negotiated tender for the public stub by Roche ($2.4 billion)
- PAREXEL in its 2017 sale to Pamplona ($5 billion)
- AMRI in its 2017 sale to Carlyle and GTCR ($1.9 billion)
- Represented financial advisor to Stemcentrix in its 2016 private company sale to Abbvie ($5.8 billion)
- Teva Pharmaceuticals in its 2015 acquisition of Auspex ($3.5 billion)
- Onyx Pharmaceuticals in its 2013 sale to Amgen ($10.4 billion)
- Ritchie Bros. in its 2023 acquisition of IAA, Inc. ($7.3 billion)
- Represented financial advisor to Momentive Global in its 2023 acquisition by Symphony Technology Group ($1.5 billion)
- PTC in its 2023 acquisition of ServiceMax ($1.46 billion)
- Citrix Systems in its 2022 go-private transaction pursuant to which affiliates of Vista Equity Partners, and Evergreen Coast Capital Corporation, an affiliate of Elliott Investment Management L.P., will acquire Citrix ($16.5 billion)
- Mimecast Limited in its 2023 acquisition by Permira ($5.8 billion)
- KIND in its 2020 acquisition by Mars, Incorporated ($5 billion)
- Twilio in its 2019 acquisition of SendGrid ($3 billion)
- Civitas in its 2019 acquisition by Centerbridge ($1.4 billion)
- PTC in its 2018 strategic partnership with Rockwell Automation ($1 billion)
- Citrix in its 2016 Reverse Morris Trust merger between a division of Citrix and LogMeIn ($2 billion)
- Xoom in its 2015 sale to PayPal ($1 billion)
- Eloqua in its 2012 sale to Oracle ($1 billion)
- Tessera Therapeutics in its 2022 Series C financing ($300 million)
- Moderna in connection with its 2020 follow-on public offerings ($500 million in March and $1.34 billion in May) 2018 record biotech initial public offering ($604 million)
- Generate Biomedicines in its 2021 Series B financing ($370 million)
- Laronde in its 2021 Series B financing ($440 million)
- Cerevel Therapeutics in its 2021 underwritten public offering ($350 million)
- Repertoire Immune Medicines in its 2021 Series B financing ($189 million)
- Aura Biosciences in connection with its:
- Rubius Therapeutics in connection with its:
- Valo Health in its:
- 2021 Series B ($300 million)
- 2022 Series C ($100 million)
- Tessera Therapeutics in its 2021 Series B financing ($230 million)
- Stuart is also retained from time to time to represent "independent" or "special" committees of the Board of Directors in complex M&A transactions, including the Transaction Committee of Sprint in Sprint Corporation’s award winning merger with T-Mobile US, Inc. (April 2020) and most recently the representation of the Special Committee of the Board of Directors of NantKwest in NantKwest’s merger with ImmunityBio (March 2021).
Community And Pro Bono Activities
Stuart serves as a member of the President's Leadership Council at Dartmouth College, as chairman emeritus of the Buckingham Browne & Nichols School and as a member of the Board of the Arthur L. Irving Institute for Energy & Society at Dartmouth College. He also served for more than a decade as a member of the Board of Fellows of Harvard Medical School.
Stuart leads the firm’s pro bono efforts on behalf of Camp Harbor View, a summer enrichment program for Boston’s youth founded by Jack Connors. Stuart is also a member of the Goodwin pro bono team advising the Boston Red Sox Foundation on Board and governance matters.
Publications and Media Mentions
Stuart has for more than a decade annually taught aspiring MBAs about the practical aspects of fiduciary duty and Board responsibility in the context of public company mergers and acquisitions, at MIT's Sloan School of Management, the Tuck School of Business Administration at Dartmouth College and the Wharton School at the University of Pennsylvania. Some of his recent speaking engagements and presentations include:
- “What’s Happening at the FTC and its Impact on Life Sciences Deal Flow,” a fireside chat with Goodwin Antitrust partner, Arman Oruc (2023 Goodwin + KPMG @ JPMorgan Symposium)
- "Diversifying the Next Generation of Board Leaders," The Corporate Director Podcast, with Alexandra Kennedy, Director of Client Services at Twitter
- “Fireside Chat with Tony Coles,” a fireside chat with industry pioneer, Tony Coles, Executive Chairman and CEO of Cerevel Therapeutics (2022 Goodwin +KPMG @ JPMorgan Symposium)
- “Fireside Chat with Noubar Afeyan,” a fireside chat with industry luminary, Noubar Afeyan, Chairman and Co-Founder of Moderna (2021 Goodwin +KPMG @ JPMorgan Symposium)
- “Healthcare Trends – Trends in the Office of the GC,” covers the ways in which life sciences and healthcare GCs are managing outside counsel and legal costs, leveraging new technologies to improve workflow and knowledge management, and remaining vigilant against persistent and rapidly shifting risks through the lens of the pandemic (2020 Goodwin Webinar)
- “M&A in 2020 and 2021,” examines the status of the current M&A market trends and potential volatility (2020 Executive Insights, Board Leaders)
- “Take-Private Transactions,” a webinar aimed at getting ahead of the recovery curve as we discussed how to navigate take-private transactions from both the buy- and sell-side perspective (2020 Goodwin’s What’s Next Webinar Series)
- “What Happens When Big Pharma Comes Knocking?,” an interactive presentation that takes participants through a public company sale process in only 60 minutes (2020 Goodwin + KPMG Symposium @ JP Morgan)
- “Responsibility to Stakeholders versus Shareholders – Part 2,” examines the recent announcement that shifts the focus of board responsibility regarding governance from shareholders to stakeholders (2019 Executive Insights, Board Leaders)
- “Responsibility to Stakeholders versus Shareholders – Part 1,” examines the recent announcement that shifts the focus of board responsibility regarding governance from shareholders to stakeholders (2019 Executive Insights, Board Leaders)
- “Governance Grab Bag: Speak for Yourself,” examines the advisability in different contexts of direct communication between a Director and a stockholder (2018 Directors Forum)
- “Governance Grab Bag: Social Studies,” delves into a Merger of Equals and the “non-economic” or social issues that are frequently the subject of negotiation in a MOE (2018 Directors Forum)
- “Governance Grab Bag: We’ve Got Bigger Problems,” decodes a Board Evaluation process and weighs the issues uncovered (2018 Directors Forum)
- “Comparing an Apple, an Orange and a Pear,” features a hypothetical public company board discussion comparing an all cash strategic M&A proposal against both an all stock strategic transaction and a private equity-backed go private transaction (2017 Directors Forum)
- “The Directors Challenge--A Lightning Round,” features a series of boardroom “crisis” case studies presented in ‘lightning rounds’ (2016 Directors Forum)
- “Sitting at the Head of the Table,” a roundtable discussion with three Board chairpersons addressing strategy, shareholder outreach and the relationship between a Board chair and the CEO (2015 Directors Forum)
- “A Foundational Transaction,” a discussion of how Boards should approach strategic partnerships when a majority stake acquisition is proposed (2015 Directors Forum)
- “Boom or Bust: Opportunities and Risk in M&A,” a panel with leading investment bankers to discuss global dealmaking in sectors including biopharma, technology and energy as well as the increasing role of activist shareholders (2015 Milken Global Conference)
Stuart is a frequent speaker on matters related to corporate governance, mergers and acquisitions, corporate finance and securities law. Some of his recent newsworthy quotes and publication features include:
- "As demand for COVID shots wanes, biotech superstar Moderna seeks its next success,” discusses the future of the pharmaceutical company Moderna post-COVID (paywall) (2023 Boston Globe)
- “Legal Deal Work Zooms Into 2021,” discusses ways in which deal parties have visibility on how companies are responding to the pandemic and practitioners have a good handle on what parameters they need to look at when conducting due diligence (2021 Mergermarket)
- “5 Trends In Biotech Dealmaking To Watch In 2021,” covers public M&A and corporate governance trends (2021 BioPharma Dive)
- “Tech M+A To Drive Busier 2021 For Deal Lawyers After Tough Year,” discusses the ways in which M&A activity bounced back in the latter half of 2020 and highlights trends to watch in the year ahead (2021 Bloomberg Law)
- “Pandemic, Democratic Wins Leave Drug Industry At Crossroads,” spotlights that M&A deal activity rose to a borderline fever pitch by the end of 2020 (2021 Bloomberg)
- “Drinks With The Deal Podcast: Goodwin Procter's Stuart Cable,” discusses Goodwin’s Life Sciences team and the ways in which Goodwin services biotech companies ranging in size from startups to multibillion-dollar public companies (2021 The Deal)
Columbia Law School
(Harlan Fiske Stone Scholar)
Tuck School of Business at Dartmouth
(magna cum laude)
Recognition & Awards
Stuart is continually recognized for his leadership in the life sciences industry on both the U.S. domestic and global levels, and has been included in numerous legal guides for his expertise.
- In 2023, Stuart and his partner Lisa Haddad were recognized by the American Lawyer as 2023 Dealmakers of the Year
- In 2023, Stuart was recognized by Chambers USA for his work in Corporate/M&A and Life Sciences
- In 2022, Stuart was recognized by Chambers USA for his work in Corporate M&A
- In 2022, Stuart was recognized by Chambers Global for his work in Corporate M&A (Int'l & Cross-Border)
- In 2022, Stuart was recognized by BTI Consulting Group as a BTI Client Service All-Star
- In 2019, Stuart was recognized by LMG Life Sciences as Corporate Attorney of the Year
- In 2017, Stuart was recognized by Law360 as Life Sciences MVP
- In 2016, Stuart was recognized by LMG Life Sciences as Life Sciences Transaction Attorney of the Year
The American Lawyer Industry Awards named Moderna and Goodwin the Best Client-Law Firm Team of 2021 – a relationship led by Stuart. Stuart has been recognized by The Best Lawyers in America Best Lawyers for his work in Corporate Law 2023.
Stuart also was recognized by the Financial Times winning its award in 2015 for Innovative Deal of the Year in advising Foundation Medicine in its $1 billion majority purchase by Roche, and in 2016 advising Citrix in its $2.6 billion Reverse Morris Trust merger with LogMeIn.
Global M&A Network has named Stuart one of the world’s top 50 M&A lawyers, recognizing his work advising Onyx Pharmaceuticals in its $10.4 billion purchase by Amgen – a transaction named 2014 Global Major Markets Life Sciences Deal of the Year.
Stuart is a fellow in the American College of Governance Counsel, a professional, educational, and honorary association of lawyers widely-recognized for their achievements in the field of corporate governance.